4528 ONO PHARMACEUTICAL CO., LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4528

TSE Prime

ONO PHARMACEUTICAL CO., LTD.

2,381.5

JPY

+79.0

(+3.43%)

Feb 2, 3:30 pm JST

15.38

USD

Feb 2, 1:30 am EST

Result

PTS

outside of trading hours

2,382.2

Feb 2, 11:48 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	361,361	103,195	105,025	80,519	162.2	56	May 11, 2022	IFRS
Mar, 2023	447,187	141,963	143,532	112,723	230.9	70	May 10, 2023	IFRS
Mar, 2024	502,672	159,935	163,734	127,977	266.6	80	May 9, 2024	IFRS
Mar, 2025	486,871	59,747	59,328	50,047	106.6	80	May 8, 2025	IFRS
Mar, 2026 Guidance	490,000	85,000	85,000	67,000	142.6	80	May 8, 2025	IFRS
YoY	+0.6%	+42.3%	+43.3%	+33.9%	+33.8%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 12, 2020	303,000	80,000	82,000	61,000	45	IFRS
	Oct 29, 2020	305,000	87,000	88,500	65,000	45	IFRS
	Feb 1, 2021	309,000	94,000	95,500	74,000	45	IFRS
	Apr 28, 2021	309,000	94,000	95,500	74,000	50	IFRS
Results	May 11, 2021	309,284	98,330	100,890	75,425	50	IFRS
Mar, 2022	May 11, 2021	Available in future release
	May 13, 2021
	Jan 31, 2022
Results	May 11, 2022
Mar, 2023	May 11, 2022
	Oct 31, 2022
Results	May 10, 2023
Mar, 2024	May 10, 2023
	Nov 1, 2023
Results	May 9, 2024
Mar, 2025	May 9, 2024
	Oct 31, 2024
	Apr 28, 2025
Results	May 8, 2025
Mar, 2026	May 8, 2025	490,000	85,000	85,000	67,000	80	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	130,728	+2.7	Available in future release
Mar, 2002	133,353	+2.0
Mar, 2003	134,993	+1.2
Mar, 2004	139,383	+3.3
Mar, 2005	145,302	+4.2
Mar, 2006	148,671	+2.3
Mar, 2007	141,711	-4.7
Mar, 2008	145,897	+3.0
Mar, 2009	136,556	-6.4
Mar, 2010	135,986	-0.4
Mar, 2011	135,255	-0.5
Mar, 2012	145,778	+7.8
Mar, 2013	142,806	-2.0
Mar, 2014	143,247	+0.3
Mar, 2015	135,775	-5.2
Mar, 2016	160,284	+18.1
Mar, 2017	244,797	+52.7
Mar, 2018	261,836	+7.0
Mar, 2019	288,634	+10.2
Mar, 2020	292,420	+1.3
Mar, 2021	309,284	+5.8
Mar, 2022	361,361	+16.8
Mar, 2023	447,187	+23.8
Mar, 2024	502,672	+12.4
Mar, 2025	486,871	-3.1
Mar, 2026 Guidance	490,000	+0.6	85,000	+42.3	85,000	+43.3	142.6	+33.8

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	502,672	159,935	31.8	16.68	14.25	0.56	266.6
Mar, 2025	486,871	59,747	12.3	6.35	5.06	0.49	106.6
Mar, 2026 Guidance	490,000	85,000	17.4	7.98	6.18	0.45	142.6

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	502,672	159,935	163,734	127,977	266.6
Fiscal Year	Mar, 2024	Mar, 2024	Mar, 2024	Mar, 2024	Mar, 2024

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	230,486	61,693	62,513	50,384	103.2	37	May 10, 2023	IFRS
Oct - Mar, 2023	243,959	62,899	64,438	53,486	111.4	40	May 9, 2024	IFRS
Oct - Mar, 2024	246,532	10,959	11,784	12,612	26.9	40	May 8, 2025	IFRS
Oct - Mar, 2025 Guidance	232,864	32,931	32,825	26,911	57.3	40	Oct 30, 2025	IFRS
YoY	-5.5%	+200.5%	+178.6%	+113.4%	+113.3%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	141,963	59,351	159,610	-100,259	-32,484	96,135	10.89	IFRS
Mar, 2024	159,935	158,737	110,660	48,077	-89,848	166,141	18.18	IFRS
Mar, 2025	59,747	-54,326	82,459	-136,785	94,299	204,567	19.23	IFRS

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2023	389,903	144,626	147,292	110,544	229.1	90.0	Jan 31, 2024	IFRS
Apr - Dec, 2024	374,562	70,754	72,037	56,592	120.5	121.4	Feb 3, 2025	IFRS
Apr - Dec, 2025	397,036	88,292	89,377	68,949	146.8	105.1	Feb 2, 2026	IFRS
YoY	+6.0%	+24.8%	+24.1%	+21.8%	+21.8%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	112,769	15,309	16,442	17,433	36.3	13.6	May 9, 2024	IFRS
Apr - Jun, 2024	117,675	30,690	33,310	24,794	52.8	26.1	Jul 31, 2024	IFRS
Jul - Sep, 2024	122,664	18,098	14,234	12,641	26.9	14.8	Oct 31, 2024	IFRS
Oct - Dec, 2024	134,223	21,966	24,493	19,157	40.8	16.4	Feb 3, 2025	IFRS
Jan - Mar, 2025	112,309	-11,007	-12,709	-6,545	-13.9	-9.8	May 8, 2025	IFRS
Apr - Jun, 2025	127,536	21,995	22,650	17,673	37.6	17.2	Aug 1, 2025	IFRS
Jul - Sep, 2025	129,600	30,074	29,525	22,416	47.7	23.2	Oct 30, 2025	IFRS
Oct - Dec, 2025	139,900	36,223	37,202	28,860	61.4	25.9	Feb 2, 2026	IFRS
YoY	+4.2%	+64.9%	+51.9%	+50.6%	+50.6%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	74,351	+10.8	Available in future release
Apr - Jun, 2021	87,363	+16.6
Jul - Sep, 2021	86,714	+14.8
Oct - Dec, 2021	97,353	+15.3
Jan - Mar, 2022	89,931	+21.0
Apr - Jun, 2022	106,722	+22.2
Jul - Sep, 2022	109,979	+26.8
Oct - Dec, 2022	122,319	+25.6
Jan - Mar, 2023	108,167	+20.3
Apr - Jun, 2023	120,016	+12.5
Jul - Sep, 2023	138,697	+26.1
Oct - Dec, 2023	131,190	+7.3
Jan - Mar, 2024	112,769	+4.3
Apr - Jun, 2024	117,675	-2.0
Jul - Sep, 2024	122,664	-11.6
Oct - Dec, 2024	134,223	+2.3
Jan - Mar, 2025	112,309	-0.4
Apr - Jun, 2025	127,536	+8.4
Jul - Sep, 2025	129,600	+5.7
Oct - Dec, 2025	139,900	+4.2	36,223	+64.9	37,202	+51.9	61.4	+50.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	139,900	55,688	56,918	42,673	87.8
Fiscal Year	Dec, 2025	Sep, 2023	Sep, 2023	Sep, 2023	Sep, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	1,519.19	84.1	882,437	741,869	709,890	0.01	May 10, 2023	IFRS
Mar, 2024	1,688.43	86.8	913,668	792,961	768,183	0.01	May 9, 2024	IFRS
Mar, 2025	1,665.61	73.5	1,064,046	782,451	790,908	0.19	May 8, 2025	IFRS
Apr - Dec, 2025	ー	77.4	1,084,397	839,670	825,743	0.15	Feb 2, 2026	IFRS

ONO PHARMACEUTICAL CO., LTD.(4528) Financial Results